Effect of an Interdisciplinary Weight Loss and Lifestyle Intervention on Obstructive Sleep Apnea Severity
The INTERAPNEA Randomized Clinical Trial

Almudena Carneiro-Barrera, PhD; Francisco J. Amaro-Gahete, PhD; Alejandro Guillén-Riquelme, PhD; Lucas Jurado-Fasoli, MSc; Germán Sáez-Roca, MD; Carlos Martín-Carrasco, MD; Gualberto Buela-Casal, PhD; Jonatan R. Ruiz, PhD

Abstract

IMPORTANCE Obesity is the leading cause of obstructive sleep apnea (OSA); however, the effects of weight loss and lifestyle interventions on OSA and comorbidities remain uncertain.

OBJECTIVE To evaluate the effect of an interdisciplinary weight loss and lifestyle intervention on OSA and comorbidities among adults with moderate to severe OSA and overweight or obesity.

DESIGN, SETTING, AND PARTICIPANTS The Interdisciplinary Weight Loss and Lifestyle Intervention for OSA (INTERAPNEA) study was a parallel-group open-label randomized clinical trial conducted at a hospital-based referral center in Granada, Spain, from April 1, 2019, to October 23, 2020. The study enrolled 89 Spanish men aged 18 to 65 years with moderate to severe OSA and a body mass index (calculated as weight in kilograms divided by height in meters squared) of 25 or greater who were receiving continuous positive airway pressure (CPAP) therapy. The sole inclusion of men was based on the higher incidence and prevalence of OSA in this population, the differences in OSA phenotypes between men and women, and the known effectiveness of weight loss interventions among men vs women.

INTERVENTIONS Participants were randomized to receive usual care (CPAP therapy) or an 8-week weight loss and lifestyle intervention involving nutritional behavior change, aerobic exercise, sleep hygiene, and alcohol and tobacco cessation combined with usual care.

MAIN OUTCOMES AND MEASURES The primary end point was the change in the apnea-hypopnea index (AHI) from baseline to the intervention end point (8 weeks) and 6 months after intervention. Secondary end points comprised changes in other OSA sleep-related outcomes, body weight and composition, cardiometabolic risk, and health-related quality of life.

RESULTS Among 89 men (mean [SD] age, 54.1 [8.0] years; all of Spanish ethnicity; mean [SD] AHI, 41.3 [22.2] events/h), 49 were randomized to the control group and 40 were randomized to the intervention group. The intervention group had a greater decrease in AHI (51% reduction; change, -21.2 events/h; 95% CI, -25.4 to -16.9 events/h) than the control group (change, 2.5 events/h; 95% CI, -2.0 to 6.9 events/h) at the intervention end point, with a mean between-group difference of -23.6 events/h (95% CI, -28.3 to -19.3 events/h). At 6 months after intervention, the reduction in AHI was 57% in the intervention group, with a mean between-group difference of -23.8 events/h (95% CI, -28.3 to -19.3 events/h). In the intervention group, 18 of 40 participants (45.0%) no longer required CPAP therapy at the intervention end point, and 6 of 40 participants (15.0%) attained complete OSA remission. At 6 months after intervention, 21 of 34 participants (61.8%) no longer required CPAP therapy, and complete remission of OSA was attained by 10 of 34 participants.

Key Points

Question Is an interdisciplinary weight loss and lifestyle intervention combined with usual care (continuous positive airway pressure [CPAP] therapy) effective for the treatment of moderate to severe obstructive sleep apnea (OSA) in men with overweight or obesity?

Findings In this randomized clinical trial involving 89 Spanish men with moderate to severe OSA who had overweight or obesity and were receiving CPAP therapy, an 8-week interdisciplinary weight loss and lifestyle intervention significantly improved OSA severity and other outcomes compared with usual care alone. At 8 weeks, 45% of participants in the intervention group no longer required CPAP therapy; at 6 months, 62% of participants in the intervention group no longer required CPAP therapy.

Meaning This study’s findings suggest that this weight loss and lifestyle intervention might be considered as a central strategy to address OSA and comorbidities.
Abstract (continued)

In the intervention vs control group, greater improvements in body weight (change, \(-7.1\) kg [95% CI, \(-8.6\) to \(-5.5\) kg] vs \(-0.3\) kg [95% CI, \(-1.9\) to \(1.4\) kg]) and composition (eg, change in fat mass, \(-2.9\) kg [95% CI, \(-4.5\) to \(-1.3\) kg] vs \(1.4\) kg [95% CI, \(-0.3\) to \(3.1\) kg]), cardiometabolic risk (eg, change in blood pressure, \(-6.5\) mm Hg [95% CI, \(-10.3\) to \(-2.6\) mm Hg] vs \(2.2\) mm Hg [95% CI, \(-2.1\) to \(6.6\) mm Hg]), and health-related quality of life (eg, change in Sleep Apnea Quality of Life Index, \(0.8\) points [95% CI, \(0.5\) to \(1.1\) points] vs \(0.1\) points [95% CI, \(-0.3\) to \(0.4\) points]) were also found at the intervention endpoint.

CONCLUSIONS AND RELEVANCE  In this study, an interdisciplinary weight loss and lifestyle intervention involving Spanish men with moderate to severe OSA and had overweight or obesity and were receiving CPAP therapy resulted in clinically meaningful and sustainable improvements in OSA severity and comorbidities as well as health-related quality of life. This approach may therefore be considered as a central strategy to address the substantial impact of this increasingly common sleep-disordered breathing condition.

TRIAL REGISTRATION  ClinicalTrials.gov Identifier: NCT03851653

Introduction

Obstructive sleep apnea (OSA), characterized by recurrent sleep state–dependent upper airway collapse, is a globally recognized major public health problem affecting up to 936 million adults in the general population, with obesity as the leading cause.\(^1,2\) Obstructive sleep apnea has emerged as a primary target of medical research and practice owing to its increasing prevalence and association with increasing rates of obesity\(^3\) and its wide spectrum of clinical and socioeconomic consequences.\(^4\) The intermittent pharyngeal obstructions occurring during sleep result in long-term exposure to hypoxia, hypercapnia, increased sympathetic activity, oxidative stress, and systemic inflammation.\(^7\) Given these pathophysiological responses, OSA has been independently associated with substantial increases in the likelihood of hypertension, dyslipidemia, diabetes, life-threatening cardiovascular diseases, and all-cause death.\(^8\)\(^\text{12}\)

The first-line treatment for OSA is the use of a continuous positive airway pressure (CPAP) device, which maintains upper airway patency through positive pressure applied with a nasal or oronasal interface.\(^13\) Although CPAP therapy is effective in reducing upper airway occlusions when used as prescribed, adherence rates are suboptimal, and long-term benefits remain uncertain.\(^13\)\(^\text{15}\) Although some studies have found that CPAP therapy has beneficial effects on blood pressure and insulin resistance,\(^16,17\) other large observational and experimental studies have reported no significant reductions in metabolic risk or cardiovascular events after long-term CPAP therapy,\(^15,18\)\(^\text{20}\) which suggests a complex and reciprocal interaction between OSA and obesity.\(^21\)

Weight loss attained through alternative or combined behavioral interventions appears to substantially improve OSA and coexisting conditions among adults.\(^22\)\(^\text{29}\) However, previous clinical trials of alternative and behavioral interventions, although enlightening, have had limitations inherent to study design or methods, including but not limited to stringent eligibility criteria, limited reported outcomes, and/or nonrandomized allocation, which restricted the generalizability of results.\(^24\)\(^\text{30}\) Furthermore, weight loss has only been addressed through restricted diets or exercise, without using either a combination of both components or behavioral approaches to promote maintenance of benefits.\(^24\) Notably, no study has, to our knowledge, focused on alcohol avoidance and smoking cessation,\(^24\) which are well-established behavioral risk factors associated with the occurrence and worsening of OSA.\(^31\)\(^\text{32}\) The Interdisciplinary Weight Loss and Lifestyle Intervention for OSA (INTERAPNEA) randomized clinical trial sought to determine the effects of a novel
interdisciplinary weight loss and lifestyle intervention on OSA severity and comorbidities among adults with moderate to severe OSA who had overweight or obesity and were receiving CPAP therapy.33

Methods

Study Design and Oversight

The INTERAPNEA study was an investigator-initiated parallel-group open-label randomized clinical trial designed to evaluate the effects of an 8-week interdisciplinary weight loss and lifestyle intervention combined with usual care (ie, CPAP therapy) vs usual care alone on OSA severity (measured by the apnea-hypopnea index [AHI]) and OSA-related comorbidities among adults with moderate to severe OSA. The clinical trial rationale, design, and methods have been published previously,33 and the full protocol and statistical analysis plan are available in Supplement 1. The study was registered and approved by all regulatory authorities and ethics committees of each collaborating center in Spain (University of Granada, Virgen de las Nieves University Hospital, and Junta de Andalucía), with all participants providing written informed consent. This study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline for randomized clinical trials.

Study Population

Eligible participants were men aged 18 to 65 years with moderate to severe OSA (AHI ≥15 events/h of sleep) who were receiving CPAP therapy and had a body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 25 or greater. The sole inclusion of men was based on the higher incidence and prevalence of OSA in this population,2 the well-established differences in OSA phenotypes between men and women,34 and the effectiveness of weight loss interventions among men vs women.24,35-37 Exclusion criteria were current participation in a weight loss program, presence of any psychological or psychiatric disorder, and coexistence of any other primary sleep disorder. The eligibility criteria were based on a thorough consideration of the potential generalizability of results; thus, no criteria regarding potential responsiveness, comorbidities, adherence rates, or use of nonhypnotic medications were established. The study sample therefore reflected the heterogeneity of men with OSA. Details about eligibility criteria and assessments used to ensure inclusion feasibility are provided in Supplement 1 and eMethods 1 in Supplement 2.

Study Recruitment, Enrollment, and Randomization

Recruitment, enrollment, and randomization of participants were performed among 3 consecutive sets of 30 to 35 participants from April 1, 2019, to January 24, 2020, with a study completion date of October 23, 2020. Participants were recruited from the outpatient sleep-disordered breathing unit of the collaborating hospital (Virgen de las Nieves University Hospital, Granada, Spain). Before enrollment, potential participants received clinical and physical examinations and completed baseline measurements to ensure inclusion feasibility. Enrolled participants were successively randomized to receive either usual care (control group) or a weight loss and lifestyle intervention combined with usual care (intervention group). Randomization was performed via a computer-generated simple (unrestricted) randomization process.38

Given the nature of the intervention, participants and clinicians were aware of clinical trial group assignments after randomization. However, the research personnel responsible for data collection and analysis were blinded to group assignments at the follow-up visits. In addition, rigorous standardization procedures for data collection and intervention were followed to ensure internal and external validity of the clinical trial.39
Study Assessments and End Points
Assessments at baseline, the intervention end point (8 weeks), and 6 months after intervention included a full-night polysomnography conducted in a laboratory, a set of questionnaires, a full-body dual-energy x-ray absorptiometry scan, and a fasting blood test. The primary end point of the INTERAPNEA clinical trial was the change in AHI at the intervention end point and 6 months after intervention, which was objectively measured during a level 1 sleep study (ie, polysomnography). The AHI measures the number of apnea and hypopnea events per hour of sleep, with 0 to 4 events indicating normal (no OSA), 5 to 14 events indicating mild OSA, 15 to 30 events indicating moderate OSA, and more than 30 events indicating severe OSA; a change of at least 15 events is considered clinically meaningful and would move a participant 2 levels in severity status (eg, from severe to mild OSA, indicating a benefit for health).

Secondary end points comprised changes in other sleep-related variables (including oxyhemoglobin desaturation index, oxygen saturation, sleep efficiency and maintenance, sleep architecture, and subjective sleep quality [measured by the Pittsburgh Sleep Quality Index]; score range, 0-21 points, with higher scores indicating worse sleep quality) and sleepiness (measured by the Epworth Sleepiness Scale; score range, 0-24 points, with higher scores indicating more daytime sleepiness), body weight and composition (including BMI; neck, chest, and waist circumference; visceral adipose tissue, and lean mass), and cardiometabolic risk measurements (including blood pressure, glucose and lipid metabolism, and liver function). Health-related quality of life (measured by the Sleep Apnea Quality of Life Index [score range, 1-7 points, with higher scores indicating better health-related quality of life]) and the physical and mental components of the Medical Outcomes Study 36-item Short-Form Health Survey [score range, 0 to 100 points, with higher scores indicating better health-related quality of life with respect to either the physical or mental component]) and lifestyle habits (including physical activity, dietary behavior [measured by the Food Behavior Checklist; score range, 23-85 points, with higher scores indicating healthier dietary patterns], alcohol consumption, and smoking) were also included as additional end points. Primary and secondary sleep-related end points as well as self-reported end points related to general physical and psychological health were measured at each study assessment after 1 week without CPAP use.

All adverse events, regardless of severity or relationship to the study intervention or participation, were systematically recorded at each of the study assessments. Serious adverse events were determined based on the guidelines adopted by the International Conference on Harmonization of Good Clinical Practice. Full descriptions of study assessments and end points are provided in eMethods 2 in Supplement 2.

Study Intervention and Control Condition
The interdisciplinary weight loss and lifestyle intervention was precisely designed and implemented based on previous research and existing evidence-based clinical practice guidelines for the management of obesity and OSA. Feasible implementation in clinical practice was also considered. As a result, the intervention was conducted for 8 weeks and comprised 5 components or modules: nutritional behavior change, moderate aerobic exercise, smoking cessation, alcohol intake avoidance, and sleep hygiene. Each component included group-based weekly sessions of 60 to 90 minutes that were led and supervised by trained professionals (A.C.-B., F.J.A.-G., and L.J.-F.) in each field. Participants in the intervention group also continued to receive usual care with CPAP therapy. A detailed intervention description, including assessment of intervention adherence and integrity, has previously been published and is also provided in eMethods 3 and eMethods 4 in Supplement 2.

In addition to usual care with CPAP therapy, participants randomized to the usual care group received general advice on weight loss and lifestyle changes from a sleep-disordered breathing specialist in a single 30-minute session. The opportunity to receive the INTERAPNEA clinical trial intervention was offered to all participants at the end of the study.
Statistical Analysis
The sample size and power of the INTERAPNEA clinical trial were estimated based on previous studies synthesized in a recent systematic review and meta-analysis. Assuming an SD of 11.98 (the AHI pooled SD found in previous research) for our primary endpoint, we estimated that enrollment of 35 participants per arm would provide statistical power of 90% at α = .05 to detect a minimum effect size of -8.36 (the pooled mean difference of previous clinical trials included in the meta-analysis) for the AHI. However, considering a maximum study withdrawal rate of 17.25% (the mean withdrawal rate of previous studies in the meta-analysis), we decided to recruit 42 participants for each study group. Owing to practical and feasibility reasons, the clinical trial was conducted among 3 consecutive sets of 30 to 35 participants.

Intervention effects on primary and secondary endpoints were assessed using linear mixed-effects models, with individual measures of growth being modeled as the function of randomization group, assessment time (baseline, 8 weeks, and 6 months after intervention), and the interaction between group and time. Estimations were performed using the restricted maximum likelihood method, including an unstructured covariance matrix to adjust for within-participant clustering resulting from the repeated-measures design.

The model assumed that missing values were missing at random; therefore, all values presented in the tables were model-based estimates. Nevertheless, attrition propensity was calculated using a logistic model estimating attrition with baseline values of the set of participants, randomization group, OSA severity, age, and BMI. Among these variables, only the set of participants significantly estimated attrition, which was attributable to the emergence of the COVID-19 pandemic at the clinical trial end point (the end point assessment of the third set of participants). Thus, the assumption that missing values in the models were missing at random was further supported; the missing at random assumption has been advocated in recent recommendations for handling missing data in randomized clinical trials affected by a pandemic, which occurred during our study. Missing data in primary and secondary sleep-related end points and secondary body composition end points were the result of participants withdrawing from the study before completion. The number of missing values in secondary cardiometabolic risk end points, including glucose and lipid metabolism and liver function end points are provided in eTable 1 in Supplement 2.

In addition, the association between changes in BMI and changes in AHI over time was examined using repeated measures correlation analysis. This statistical technique is used to determine the within-individual association for paired measures assessed on 2 or more occasions among multiple individuals.

All estimations and analyses were performed using an intention-to-treat approach (including all participants as they were originally randomized) and an additional per-protocol approach that was restricted to participants with CPAP use of 4 hours or more per night on 70% of nights and, among the intervention group, an 80% or greater attendance rate for intervention sessions. Hypothesis testing was 2-sided, with P < .05 considered statistically significant. All analyses were conducted using R software, version 4.0.3 (R Foundation for Statistical Computing); linear mixed-effects models were performed using the lme4 package for R software.

Intervention effect assessments were based not only on statistical and practical significance but on a practical benefit approach emphasizing and reporting unadjusted values that are intuitive to human judgment and readily replicable considering the design and methods used in this study.

Results
Study Participants
Among 156 men initially screened for participation, 89 were enrolled and randomized to either the control group (49 participants) or the intervention group (40 participants) (Figure 1). Overall, 14 participants (15.7%; all from the control group) were unavailable for follow-up at the intervention end point, owing mainly to the onset of the COVID-19 pandemic (10 participants). A total of 89
participants were thus included in the intention-to-treat analysis and, according to prespecified adherence criteria, 75 participants were included in the additional per-protocol analysis (information about intervention adherence is available in eMethods 4 in Supplement 2).

Among 89 men, the mean (SD) age was 54.1 (8.0) years, the mean (SD) AHI was 41.3 (22.2) events/h, and the mean (SD) BMI was 34.4 (5.4). All participants were of Spanish ethnicity. Participants had a mean (SD) walking distance of 5.6 (3.9) km/d; 24 participants (27.0%) were current smokers, and 65 participants (73.0%) reported light to moderate alcohol intake. Baseline sociodemographic and clinical characteristics were fairly well balanced between the intervention vs control group (eg, mean [SD] age, 52.6 [7.1] years vs 55.3 [8.5] years; mean [SD] AHI, 41.6 [23.5] events/h vs 41.1 [21.3] events/h; mean [SD] BMI, 35.0 [6.0] vs 33.9 [4.8]) (Table 1). Baseline characteristics were equivalent when adopting a per-protocol approach (eTable 2 in Supplement 2).
Table 1. Baseline Participant Characteristics

| Characteristic                  | Participants, No. (%) | Control group | Intervention group |
|--------------------------------|-----------------------|---------------|--------------------|
| Total participants, No.        | 49                    | 40            |                    |
| Age, mean (SD), y              | 55.3 (8.5)            | 52.6 (7.1)    |                    |
| Educational level              |                       |               |                    |
| Primary education              | 13 (26.5)             | 10 (25.0)     |                    |
| Secondary education            | 10 (20.4)             | 6 (15.0)      |                    |
| Vocational education           | 13 (26.5)             | 17 (42.5)     |                    |
| Higher education               | 13 (26.5)             | 7 (17.5)      |                    |
| Marital status                 |                       |               |                    |
| Single                         | 7 (14.3)              | 2 (5.0)       |                    |
| Married                        | 34 (69.4)             | 34 (85.0)     |                    |
| Divorced                       | 8 (16.3)              | 4 (10.0)      |                    |
| Occupational status            |                       |               |                    |
| Employed                       | 27 (55.1)             | 21 (52.5)     |                    |
| Self-employed                  | 8 (16.3)              | 12 (30.0)     |                    |
| Unemployed                     | 4 (8.2)               | 5 (12.5)      |                    |
| Retired                        | 10 (20.4)             | 2 (5.0)       |                    |
| Medical conditionsb            |                       |               |                    |
| Hypertension                   | 33 (67.3)             | 27 (67.5)     |                    |
| Type 2 diabetes                | 12 (24.5)             | 10 (25.0)     |                    |
| Cardiovascular disease         | 9 (18.4)              | 7 (17.5)      |                    |
| Other                          | 29 (59.2)             | 26 (65.0)     |                    |
| Medicationsb                   |                       |               |                    |
| Antihypertensive               | 31 (63.3)             | 24 (60.0)     |                    |
| Statin                         | 15 (30.6)             | 7 (17.5)      |                    |
| Oral antidiabetic              | 5 (10.2)              | 2 (5.0)       |                    |
| Insulin                        | 3 (6.1)               | 1 (2.5)       |                    |
| α-Blocker                      | 7 (14.3)              | 5 (12.5)      |                    |
| Polymedicationc                | 14 (28.6)             | 6 (15.0)      |                    |
| Body height, mean (SD), cm     | 171 (7.9)             | 172 (6.3)     |                    |
| Body weight status             |                       |               |                    |
| Overweight                     | 10 (20.4)             | 5 (12.5)      |                    |
| Obese                          |                       |               |                    |
| Class 1                        | 21 (42.9)             | 19 (47.5)     |                    |
| Class 2                        | 16 (32.7)             | 11 (27.5)     |                    |
| Class 3                        | 2 (4.1)               | 5 (12.5)      |                    |
| OSA                            |                       |               |                    |
| Moderate                       | 20 (40.8)             | 15 (37.5)     |                    |
| Severe                         | 29 (59.2)             | 25 (62.5)     |                    |
| Time since OSA diagnosis, mean (SD), y | 7.4 (5.7) | 6.5 (6.5) |                    |
| Physical activity, mean (SD), km/d | 5.2 (3.9) | 6.1 (3.8) |                    |
| Food Behavior Checklist score, mean (SD)d | 59.1 (9.3) | 59.5 (8.5) |                    |
| Alcohol consumption            |                       |               |                    |
| Never                          | 11 (22.4)             | 13 (32.5)     |                    |
| Occasionally                   | 12 (24.5)             | 8 (20.0)      |                    |
| Frequently                     | 15 (30.6)             | 12 (30.0)     |                    |
| Daily                          | 11 (22.4)             | 7 (17.5)      |                    |
| Tobacco consumption            |                       |               |                    |
| Nonsmoker                      | 17 (34.7)             | 15 (37.5)     |                    |
| Ex-smoker                      | 18 (36.7)             | 15 (37.5)     |                    |
| Smoker                         | 14 (28.6)             | 10 (25.0)     |                    |

Abbreviation: OSA, obstructive sleep apnea.

* No significant between-group differences were observed in any of the baseline characteristics.

b Participants could have more than 1 condition or medication.

c Defined as the use of 5 or more medications.

d Score range, 23-85 points, with higher scores indicating healthier dietary patterns.
Primary and Secondary Sleep-Related End Points

Participants in the intervention group experienced a reduction in AHI from 41.6 events/h at baseline to 20.4 events/h at the intervention endpoint (51% reduction; change in AHI, –21.2 events/h; 95% CI, –25.4 to –16.9 events/h) and 17.8 events/h at 6 months after intervention (57% reduction; change in AHI, –23.8 events/h; 95% CI, –28.3 to –19.3 events/h). No discernible differences in AHI were observed in the control group at the intervention endpoint (change, 2.5 events/h; 95% CI, –2.0 to 6.9 events/h) or at 6 months after intervention (change, –0.8 events/h; 95% CI, –5.8 to 4.1 events/h). The mean difference in AHI change between groups was –23.6 events/h (95% CI, –28.7 to –18.5 events/h; P < .001) at the intervention endpoint and –23.0 events/h (95% CI, –28.4 to –17.4 events/h; P < .001) at 6 months after intervention (Table 2).

According to AHI thresholds for OSA severity, at the intervention endpoint, 23 of 40 participants (57.5%) in the intervention group improved by 1 category, with 3 of 25 participants (12.0%) improving from severe to mild OSA and 6 of 40 participants (15.0%) experiencing complete remission of OSA (Figure 2; eFigure 1 in Supplement 2). At 6 months after intervention, 14 of 34 participants (41.1%) in the intervention group improved by 1 category, with 5 of 21 participants (23.8%) improving from severe to mild OSA and 10 of 34 participants (29.4%) experiencing complete remission of OSA. Notably, in the intervention group, 18 of 40 participants (45.0%) no longer required CPAP therapy at the intervention endpoint, and 21 of 34 participants (61.8%) no longer required CPAP therapy at 6 months after intervention; cessation of this therapy was counseled based on OSA severity reduction to a mild category and the absence of concomitant symptoms of sleepiness, impaired cognition, mood disturbance, insomnia, or other conditions, such as hypertension, ischemic heart disease, or history of stroke.

In the intervention group, similar results were observed for changes in oxyhemoglobin saturation end points (eg, oxyhemoglobin desaturation index: change at 8 weeks, –16.0 events/h [95% CI, –21.4 to –10.7 events/h]; change at 6 months, –23.5 events/h [95% CI, –29.2 to –17.8 events/h]), sleep efficiency (change at 8 weeks, 5.7% [95% CI, 2.5%–8.8%]; change at 6 months, 7.6% [95% CI, 4.3%–10.9%]), sleep maintenance (eg, wake after sleep onset: change at 8 weeks, –17.2 minutes [95% CI, –32.5 to –1.9 minutes]; change at 6 months, –25.8 minutes [95% CI, –41.9 to –9.7 minutes]), sleep architecture (eg, rapid eye movement sleep: change at 8 weeks, 2.5% [95% CI, 0.3%–4.7%]; change at 6 months, 4.5% [95% CI, 2.2%–6.8%]), subjective sleep quality (Pittsburgh Sleep Quality Index: change at 8 weeks, –2.8 points [95% CI, –3.8 to –1.8 points]; change at 6 months, –3.6 points [95% CI, –4.7 to –2.5 points]), and sleepiness (Epworth Sleepiness Scale: change at 8 weeks, –4.6 points [95% CI, –6.3 to –2.9 points]; change at 6 months, –6.8 points [95% CI, –8.6 to –5.0 points]). These results were almost identical to those obtained using the per-protocol approach (eTable 3 in Supplement 2).

With regard to changes from the intervention endpoint to 6 months after intervention, participants in the intervention group not only maintained improvements in all sleep-related end points but continued to experience significant improvements in oxyhemoglobin desaturation index (change, –7.4 events/h; 95% CI, –13.1 to –1.7 events/h) and sleepiness (change in Epworth Sleepiness Scale score, –2.2 points; 95% CI, –4.0 to –0.4 points) (eFigure 2 and eTable 4 in Supplement 2). Individual values at baseline, the intervention endpoint, and 6 months after intervention and changes in AHI (primary end point) by group are shown in Figure 2. Reductions in BMI were significantly associated with changes in AHI over time; decreases in BMI were correlated with reductions in AHI (r = 0.83; P < .001) (eFigure 3 in Supplement 2).

Body Composition and Cardiometabolic Risk

Participants in the intervention group had greater reductions in body weight at the intervention endpoint (change, –71 kg; 95% CI, –8.6 to –5.5 kg) than participants in the control group (change, –0.3 kg; 95% CI, –1.9 to 1.4 kg), with a mean difference of –6.8 kg (95% CI, –8.7 to –4.9 kg; P < .001) between groups (Table 3). Similar results were found at 6 months after intervention (change, –6.9 kg [95% CI, –8.5 to 5.2 kg] in the intervention group vs –1.2 kg [95% CI, –3.0 to 0.6 kg] in the control
Table 2. Primary and Secondary Sleep-Related End Points

| End point                                      | Control group (n = 49) | Intervention group (n = 40) | Mean difference between groups a |
|------------------------------------------------|------------------------|----------------------------|---------------------------------|
| **Primary**                                    |                        |                            |                                 |
| AHI, events/h (95% CI)                         |                        |                            |                                 |
| Baseline                                       | 41.1 (35.3 to 46.9)    | 41.6 (35.1 to 48.0)        | NA                              |
| Change at 8 wk                                 | 2.5 (-2.0 to 6.9)      | -21.2 (-25.4 to -16.9)     | -23.6 (-28.7 to -18.5) b         |
| Change at 6 mo                                 | -0.8 (-5.8 to 4.1)     | -23.8 (-28.3 to -19.3)     | -23.0 (-28.4 to -17.4) b         |
| **Secondary**                                  |                        |                            |                                 |
| Oxyhemoglobin desaturation index ≥3%, events/h (95% CI) |                        |                            |                                 |
| Baseline                                       | 45.4 (39.0 to 51.7)    | 45.4 (38.4 to 52.5)        | NA                              |
| Change at 8 wk                                 | 3.0 (-2.7 to 8.6)      | -16.0 (-21.4 to -10.7)     | -19.0 (-25.4 to -12.6) b         |
| Change at 6 mo                                 | -0.8 (-7.0 to 5.5)     | -23.5 (-29.2 to -17.8)     | -22.7 (-29.6 to -15.7) b         |
| Mean SpO2, % (95% CI)                          |                        |                            |                                 |
| Baseline                                       | 90.3 (89.3 to 91.2)    | 91.3 (90.3 to 92.3)        | NA                              |
| Change at 8 wk                                 | -0.6 (-1.8 to 0.5)     | 1.5 (0.4 to 2.6)           | 2.1 (0.8 to 3.4) c               |
| Change at 6 mo                                 | -0.8 (-2.1 to 0.5)     | 2.6 (1.4 to 3.8)           | 3.4 (1.9 to 4.8) b               |
| SpO2 nadir, % (95% CI)                         |                        |                            |                                 |
| Baseline                                       | 76.8 (74.2 to 79.3)    | 78.1 (75.2 to 80.9)        | NA                              |
| Change at 8 wk                                 | 0.3 (-1.6 to 2.2)      | 2.8 (1.0 to 4.6)           | 2.5 (0.3 to 4.7) d               |
| Change at 6 mo                                 | -1.6 (-3.7 to 0.6)     | 4.4 (2.5 to 6.4)           | 6.0 (3.6 to 8.4) e               |
| Sleep time with SpO2 <90%, % (95% CI)          |                        |                            |                                 |
| Baseline                                       | 11.3 (8.2 to 14.3)     | 9.1 (5.7 to 12.5)          | NA                              |
| Change at 8 wk                                 | 1.7 (-1.8 to 5.2)      | -4.4 (-7.8 to -1.1)        | -6.1 (-10.1 to 2.1) e             |
| Change at 6 mo                                 | 1.1 (-2.7 to 5.0)      | -5.5 (-9.0 to -1.9)        | -6.6 (-10.9 to -2.3) e           |
| Sleep efficiency, % (95% CI)                   |                        |                            |                                 |
| Baseline                                       | 85.6 (83.6 to 87.7)    | 86.0 (83.8 to 88.3)        | NA                              |
| Change at 8 wk                                 | -1.7 (-4.9 to 1.5)     | 5.7 (2.5 to 8.8)           | 7.4 (3.7 to 11.1) f              |
| Change at 6 mo                                 | -1.6 (-5.2 to 1.9)     | 7.6 (4.3 to 10.9)          | 9.2 (5.2 to 13.2) g              |
| Sleep latency, min (95% CI)                    |                        |                            |                                 |
| Baseline                                       | 21.5 (17.5 to 25.6)    | 23.0 (18.5 to 27.5)        | NA                              |
| Change at 8 wk                                 | 2.9 (-4.3 to 10.1)     | -7.1 (-14.3 to 0.1)        | -10.0 (-18.3 to -1.6) f           |
| Change at 6 mo                                 | 4.5 (-3.3 to 12.3)     | -11.2 (-18.8 to -3.7)      | -15.7 (-24.6 to -6.8) g           |
| Wake after sleep onset, min (95% CI)           |                        |                            |                                 |
| Baseline                                       | 54.4 (44.4 to 64.4)    | 47.6 (36.5 to 58.7)        | NA                              |
| Change at 8 wk                                 | 11.7 (-3.8 to 27.3)    | -17.2 (-32.5 to -1.9)      | -28.9 (-46.8 to -11.0) i          |
| Change at 6 mo                                 | 9.4 (-7.7 to 26.5)     | -25.8 (-41.9 to -9.7)      | -35.2 (-54.4 to -15.8) e          |
| N1 plus N2 sleep, % (95% CI)                   |                        |                            |                                 |
| Baseline                                       | 64.9 (62.5 to 67.3)    | 63.4 (60.8 to 66.0)        | NA                              |
| Change at 8 wk                                 | 3.4 (-0.4 to 7.1)      | -6.2 (-9.8 to -2.5)        | -9.5 (-13.9 to -5.2) g           |
| Change at 6 mo                                 | 4.9 (0.7 to 9.0)       | -8.9 (-12.8 to -5.0)       | -13.8 (-18.4 to -9.1) g           |
| N3 sleep, % (95% CI)                            |                        |                            |                                 |
| Baseline                                       | 20.6 (18.6 to 22.5)    | 20.4 (18.2 to 22.6)        | NA                              |
| Change at 8 wk                                 | -3.4 (-7.4 to -1.0)    | 3.7 (0.5 to 6.9)           | 7.9 (4.1 to 11.6) g              |
| Change at 6 mo                                 | -7.4 (-10.9 to -3.8)   | 4.5 (1.1 to 7.8)           | 11.8 (7.8 to 15.9) p             |
| REM sleep, % (95% CI)                           |                        |                            |                                 |
| Baseline                                       | 14.5 (13.2 to 15.8)    | 16.2 (14.8 to 17.7)        | NA                              |
| Change at 8 wk                                 | 0.9 (-1.3 to 3.1)      | 2.5 (0.3 to 4.7)           | 1.6 (-1.0 to 4.1)                |
| Change at 6 mo                                 | 2.7 (0.3 to 5.1)       | 4.5 (2.2 to 6.8)           | 1.8 (-0.9 to 4.5)                |
| AHI during REM sleep, events/h (95% CI)        |                        |                            |                                 |
| Baseline                                       | 41.6 (36.0 to 47.2)    | 45.1 (39.0 to 51.3)        | NA                              |
| Change at 8 wk                                 | 5.2 (-2.6 to 13.0)     | -22.6 (-30.2 to -15.1)     | -27.8 (-36.7 to -18.9) b          |
| Change at 6 mo                                 | -3.6 (-12.2 to 4.9)    | -26.6 (-34.6 to -18.6)     | -21.0 (-32.6 to -13.3) b          |

(continued)
Participants in the intervention vs control group had greater reductions in BMI (change at 8 weeks, −2.5 [95% CI, −3.0 to −1.9] vs −0.2 [95% CI, −0.8 to 0.4]; change at 6 months, −2.4 [95% CI, −3.0 to −1.8] vs −0.6 [95% CI, −1.2 to −0.02]), neck circumference (change at 8 weeks, −2.5 cm [95% CI, −2.8 to −1.7 cm] vs −0.3 cm [95% CI, −0.9 to 0.2 cm]; change at 6 months, −2.9 cm [95% CI, −3.5 to −2.3] vs 0.2 cm [95% CI, −0.5 to 0.8 cm]), chest circumference (change at 8 weeks, −3.4 cm [95% CI, −4.6 to −2.1 cm] vs 0.5 cm [95% CI, −0.8 to 1.8 cm]; change at 6 months, −4.1 cm [95% CI, −5.4 to −2.8 cm] vs 0.7 cm [95% CI, −0.8 to 2.1 cm]), waist circumference (change at 8 weeks, −6.9 cm [95% CI, −8.3 to −5.5 cm] vs −0.2 cm [95% CI, −0.2 to 1.3 cm]; change at 6 months, −8.8 cm [95% CI, −10.3 to −7.2 cm] vs 0.3 cm [95% CI, −1.4 to 2.0 cm]), fat mass (change at 8 weeks, −2.9 kg [95% CI, −4.5 to −1.3 kg] vs 1.4 kg [95% CI, −0.3 to 3.1 kg]); change at 6 months, −6.5 kg [95% CI, −8.2 to −4.8 kg] vs 0.2 kg [−1.7 to 2.1 kg]), and visceral adipose tissue (change at 8 weeks, −106.2 g [95% CI, −187.2 to −25.3 g] vs 32.6 g [95% CI, −52.0 to 117.1 g]; change at 6 months, −268.4 g [95% CI, −354.3 to −182.6 g] vs −26.3 g [95% CI, −119.7 to 67.1 g]). At 6 months after intervention, body weight decreased by 7%, fat mass by 19%, and visceral adipose tissue by 26% in the intervention group.

Greater improvements in cardiometabolic risk (including blood pressure and glucose and lipid metabolism) and liver function end points were also found in the intervention vs control group at both the intervention end point (eg, change in blood pressure, −6.5 mm Hg [95% CI, −10.3 to −2.6 mm Hg] vs 2.2 mm Hg [95% CI, −2.1 to 6.6 mm Hg]); change in γ-glutamyltransferase level, −11.2 IU/L [95% CI, −18.9 to −3.5 IU/L] vs 3.7 IU/L [95% CI, −4.7 to 12.0 IU/L]; to convert to μkat/L, multiply by 0.017) and 6 months after intervention (eg, change in blood pressure, −9.6 mm Hg [95% CI, −13.6 to −5.5 mm Hg] vs 2.3 mm Hg [95% CI, −2.2 to 6.8 mm Hg]; change in γ-glutamyltransferase level, −14.0 IU/L [95% CI, −22.2 to −5.9 IU/L] vs 0.5 IU/L [95% CI, −8.4 to 9.5 IU/L]) (Table 3). These results were almost identical to those obtained using the per-protocol approach (eTable 5 in Supplement 2). With regard to changes from the intervention end point to 6 months after intervention, benefits in body composition and cardiometabolic risk end points among the intervention group were not only sustained but significantly increased, as revealed by significant reductions in neck circumference (change, −0.7 cm; 95% CI, −1.2 to −0.1 cm), waist circumference (change, −1.8 cm; 95% CI, −3.3 to −0.02 cm).
−0.3 cm), fat mass (change, −3.6 kg; 95% CI, −5.3 to −1.9 kg), and systolic blood pressure (change, −6.0 mm Hg; 95% CI, −10.4 to −1.5 mm Hg), among others (eTable 6 in Supplement 2).

Health-Related Quality of Life and Lifestyle
Health-related quality of life in the intervention vs control group was significantly improved at the intervention end point and 6 months after intervention, as shown by changes in scores on the Sleep Apnea Quality of Life Index (change at 8 weeks, 0.8 points [95% CI, 0.5-1.1 points] vs 0.1 points [95% CI, −0.3 to 0.4 points]; change at 6 months, 1.1 points [95% CI, 0.7-1.5 points] vs 0.1 points [95% CI, 0.7-1.5 points]).

The endsoftheboxesintheboxplotsarelocatedatthefirstandthirdquartiles,withthe black linethemiddleillustratingthemedian. Whiskersextendtotheupperandlower adjacent values, the location of the furthest point within a distance of 1.5 IQRs from the first and third quartiles. The parallel line plot contains 1 vertical line for each participant, which extends from their baseline value to their 8-week or 6-month value. Descending lines indicate an improvement in the outcome. Baseline values are placed in ascending order for the control group and descending order for the intervention group. The apnea-hypopnea index measures the number of apnea and hypopnea events per hour of sleep, with 0-4 events indicating normal (no obstructive sleep apnea [OSA]), 5-14 events indicating mild OSA, 15-30 events indicating moderate OSA, and >30 events indicating severe OSA; a change of at least 15 events is considered clinically meaningful and would move a participant 2 levels in severity status (eg, from severe to mild OSA, indicating a benefit for health).
Table 3. Secondary Body Composition and Cardiometabolic Risk End Points

| End point                      | Control group (n = 49) | Intervention group (n = 40) | Mean difference between groupsᵃ |
|--------------------------------|------------------------|-----------------------------|---------------------------------|
| **Body weight and composition**|                        |                             |                                 |
| Body weight, kg (95% CI)       | Baseline: 99.6 (94.5 to 104.6) | 103.3 (97.6 to 108.9) | NA                             |
| Change at 8 wk                 | -0.3 (-1.9 to 1.4)    | -7.1 (-8.6 to -5.5)       | -6.8 (-8.7 to -4.9)ᵇ            |
| Change at 6 mo                 | -1.2 (-3.0 to 0.6)    | -6.9 (-8.5 to -5.2)       | -5.7 (-7.7 to -3.6)ᵇ            |
| BMI (95% CI)                   | Baseline: 33.9 (32.4 to 35.5) | 35.0 (33.4 to 36.7) | NA                             |
| Change at 8 wk                 | -0.2 (-0.8 to 0.4)    | -2.5 (-3.0 to -1.9)       | -2.3 (-2.9 to -1.6)ᵇ            |
| Change at 6 mo                 | -0.6 (-1.2 to 0.02)   | -2.4 (-3.0 to -1.8)       | -1.8 (-2.5 to -1.1)ᵇ            |
| Neck circumference, cm (95% CI)| Baseline: 45.5 (44.4 to 46.5) | 45.0 (43.9 to 46.2) | NA                             |
| Change at 8 wk                 | -0.3 (-0.9 to 0.2)    | -2.3 (-2.8 to -1.7)       | -1.9 (-2.6 to -1.3)ᵇ            |
| Change at 6 mo                 | 0.2 (-0.5 to 0.8)     | -2.9 (-3.5 to -2.3)       | -3.1 (-3.8 to -2.4)ᵇ            |
| Chest circumference, cm (95% CI)| Baseline: 117.4 (114.5 to 120.2) | 118.0 (114.9 to 121.2) | NA                             |
| Change at 8 wk                 | 0.5 (-0.8 to 1.8)     | -3.4 (-4.6 to -2.1)       | -3.8 (-5.3 to -2.4)ᵇ            |
| Change at 6 mo                 | 0.7 (-0.8 to 2.1)     | -4.1 (-5.4 to -2.8)       | -4.8 (-6.4 to -3.2)ᵇ            |
| Waist circumference, cm (95% CI)| Baseline: 117.9 (114.3 to 121.5) | 119.0 (115.0 to 122.9) | NA                             |
| Change at 8 wk                 | -0.2 (-1.7 to 1.3)    | -6.9 (-8.3 to -5.5)       | -6.8 (-8.5 to -5.0)ᵇ            |
| Change at 6 mo                 | 0.3 (-1.4 to 2.0)     | -8.8 (-10.3 to -7.2)      | -9.0 (-10.9 to -7.2)ᵇ           |
| Fat mass, kg (95% CI)          | Baseline: 33.8 (31.0 to 36.7) | 34.9 (31.8 to 38.0) | NA                             |
| Change at 8 wk                 | 1.4 (-0.3 to 3.1)     | -2.9 (-4.5 to -1.3)       | -4.3 (-6.2 to -2.4)ᵇ            |
| Change at 6 mo                 | 0.2 (-1.7 to 2.1)     | -6.5 (-8.2 to -4.8)       | -6.6 (-8.7 to -4.6)ᵇ            |
| Visceral adipose tissue, g (95% CI)| Baseline: 1049.2 (969.8 to 1128.5) | 1017.3 (929.5 to 1105.2) | NA                             |
| Change at 8 wk                 | 32.6 (-52.0 to 117.1) | -106.2 (-187.2 to -25.3)  | -138.8 (-234.7 to -42.6)ᶜ       |
| Change at 6 mo                 | -26.3 (-119.7 to 67.1) | -268.4 (-354.3 to -182.6) | -242.2 (-346.1 to -137.8)ᵇ      |
| Lean mass, kg (95% CI)         | Baseline: 60.8 (58.3 to 63.4) | 61.0 (60.2 to 65.8) | NA                             |
| Change at 8 wk                 | -2.2 (-3.5 to -0.9)   | -2.7 (-4.0 to -1.5)       | -0.5 (-2.0 to 0.9)              |
| Change at 6 mo                 | -1.3 (-2.7 to -0.2)   | 0.3 (-1.0 to 1.6)         | 1.6 (-0.1 to 3.2)              |
| **Cardiometabolic risk**       |                        |                             |                                 |
| BP Systolic, mm Hg (95% CI)    | Baseline: 142.3 (138.3 to 146.3) | 143.7 (139.2 to 148.1) | NA                             |
| Change at 8 wk                 | -0.7 (-5.1 to 3.6)    | -7.9 (-12.1 to -3.7)      | -7.2 (-12.2 to -2.2)ᶜ           |
| Change at 6 mo                 | 2.6 (-2.2 to 7.4)     | -13.9 (-18.3 to -9.5)     | -16.5 (-21.9 to -11.1)ᵇ         |
| BP Diastolic, mm Hg (95% CI)   | Baseline: 82.1 (79.0 to 85.2) | 84.0 (80.6 to 87.4) | NA                             |
| Change at 8 wk                 | 0.2 (-4.4 to 4.8)     | -5.7 (-10.3 to -1.2)      | -6.0 (-11.3 to -0.6)ᵃ           |
| Change at 6 mo                 | 2.0 (-3.1 to 7.1)     | -7.4 (-12.1 to -2.6)      | -9.3 (-15.1 to -3.6)ᵃ           |
| Mean BP, mm Hg (95% CI)        | Baseline: 102.2 (99.2 to 105.2) | 103.9 (100.6 to 107.2) | NA                             |
| Change at 8 wk                 | 2.2 (-2.1 to 6.6)     | -6.5 (-10.3 to -2.6)      | -6.4 (-10.9 to -1.9)ᵇ           |
| Change at 6 mo                 | 2.3 (-2.2 to 6.8)     | -9.6 (-13.6 to -5.5)      | -11.8 (-16.6 to -6.9)ᵇ          |

(continued)
Table 3. Secondary Body Composition and Cardiometabolic Risk End Points (continued)

| End point                | Control group (n = 49) | Intervention group (n = 40) | Mean difference between groups* |
|--------------------------|------------------------|-----------------------------|---------------------------------|
| Glucose metabolism      |                        |                             |                                 |
| Glucose, mg/dL (95% CI) |                        |                             |                                 |
| Baseline                 | 102.0 (96.0 to 107.9)  | 95.5 (89.1 to 102.0)        | NA                              |
| Change at 8 wk           | 0.1 (-4.9 to 5.1)      | -6.7 (-11.4 to -2.0)        | -6.8 (-12.4 to -1.2)            |
| Change at 6 mo           | 3.6 (-1.9 to 9.0)      | -6.6 (-11.6 to -1.6)        | -10.2 (-16.2 to -4.1)           |
| Insulin, IU/mL (95% CI)  |                        |                             |                                 |
| Baseline                 | 14.1 (11.9 to 16.2)    | 13.0 (10.7 to 15.3)         | NA                              |
| Change at 8 wk           | 1.6 (-0.5 to 3.7)      | -4.9 (-6.9 to -2.9)         | -6.5 (-8.9 to -4.2)             |
| Change at 6 mo           | 0.3 (-2.0 to 2.5)      | -5.2 (-7.3 to -3.1)         | -5.4 (-8.0 to -2.9)             |
| HOMA-IR index, score (95% CI) |                    |                             |                                 |
| Baseline                 | 3.5 (2.7 to 4.2)       | 3.2 (2.3 to 4.0)            | NA                              |
| Change at 8 wk           | 0.5 (-0.6 to 1.6)      | -1.3 (-2.4 to -0.3)         | -1.9 (-3.1 to -0.6)             |
| Change at 6 mo           | 0.4 (-0.8 to 1.6)      | -1.4 (-2.5 to -0.3)         | -1.8 (-3.1 to -0.5)             |
| Lipid metabolism        |                        |                             |                                 |
| Total cholesterol, mg/dL (95% CI) |                    |                             |                                 |
| Baseline                 | 176.4 (165.8 to 187.1) | 189.6 (178.1 to 201.0)      | NA                              |
| Change at 8 wk           | 6.4 (-4.4 to 17.2)     | -19.4 (-29.5 to -9.3)       | -25.8 (-37.9 to -13.7)          |
| Change at 6 mo           | 5.7 (-6.0 to 17.4)     | -16.6 (-27.3 to -5.9)       | -22.3 (-35.3 to -9.3)           |
| HDL-C, mg/dL (95% CI)    |                        |                             |                                 |
| Baseline                 | 44.7 (41.5 to 47.8)    | 47.1 (43.9 to 50.3)         | NA                              |
| Change at 8 wk           | 1.9 (-0.9 to 4.8)      | 0.2 (-2.2 to 2.6)           | -1.7 (-4.7 to 1.3)              |
| Change at 6 mo           | 0.7 (-2.5 to 3.8)      | 3.0 (0.5 to 5.4)            | 2.3 (-1.0 to 5.6)               |
| LDL-C, mg/dL (95% CI)    |                        |                             |                                 |
| Baseline                 | 113.0 (103.7 to 122.3) | 119.5 (110.1 to 128.9)      | NA                              |
| Change at 8 wk           | 0.5 (-8.9 to 10.0)     | -15.0 (-22.9 to -7.1)       | -15.5 (-25.5 to -5.5)           |
| Change at 6 mo           | 8.2 (-2.3 to 18.7)     | -14.2 (-22.4 to -6.0)       | -22.4 (-33.3 to -11.6)          |
| Triglycerides, mg/dL (95% CI) |                    |                             |                                 |
| Baseline                 | 156.5 (136.3 to 176.7) | 129.5 (107.7 to 151.2)      | NA                              |
| Change at 8 wk           | 1.5 (-19.1 to 22.2)    | -24.5 (-43.7 to -5.2)       | -26.0 (-49.2 to -2.9)           |
| Change at 6 mo           | 8.3 (-14.0 to 30.6)    | -23.7 (-44.1 to -3.3)       | -32.0 (-56.9 to -7.3)           |
| Apolipoprotein A1, mg/dL (95% CI) |                    |                             |                                 |
| Baseline                 | 128.1 (122.4 to 133.7) | 131.0 (124.9 to 137.1)      | NA                              |
| Change at 8 wk           | 5.7 (-0.5 to 12.0)     | -0.6 (-6.5 to 5.4)          | -6.3 (-13.4 to 0.7)             |
| Change at 6 mo           | 0.9 (-5.5 to 7.4)      | 9.5 (3.6 to 15.5)           | 8.6 (1.4 to 15.8)               |
| Apolipoprotein B, mg/dL (95% CI) |                    |                             |                                 |
| Baseline                 | 96.2 (89.9 to 102.6)   | 102.5 (95.6 to 109.3)       | NA                              |
| Change at 8 wk           | 2.2 (-4.3 to 8.8)      | -11.9 (-18.2 to -5.6)       | -14.1 (-21.6 to -6.7)           |
| Change at 6 mo           | -1.1 (-7.8 to 5.7)     | -15.2 (-21.5 to -8.9)       | -14.1 (-21.7 to -6.6)           |
| Liver function           |                        |                             |                                 |
| AST, IU/L (95% CI)       |                        |                             |                                 |
| Baseline                 | 25.3 (22.3 to 28.3)    | 25.3 (22.2 to 28.4)         | NA                              |
| Change at 8 wk           | 0.7 (-3.6 to 5.0)      | -2.4 (-6.3 to 1.5)          | -3.1 (-7.8 to 1.6)              |
| Change at 6 mo           | -0.7 (-5.1 to 3.6)     | -4.8 (-8.7 to -0.9)         | -4.0 (-8.8 to 0.7)              |
| ALT, IU/L (95% CI)       |                        |                             |                                 |
| Baseline                 | 28.9 (24.9 to 32.9)    | 29.6 (25.3 to 34.0)         | NA                              |
| Change at 8 wk           | 0.5 (-4.6 to 5.6)      | -4.0 (-8.9 to 0.8)          | -4.6 (-10.4 to 1.2)             |
| Change at 6 mo           | -0.2 (-5.8 to 5.3)     | -7.1 (-12.3 to -2.0)        | -6.9 (-13.1 to -0.6)            |

(continued)
Participants in the intervention group who reported light to moderate alcohol consumption at baseline (27 of 40 individuals [67.5%]) reduced their alcohol intake to complete abstinence from the first week of the intervention to the intervention endpoint. At 6 months after intervention, 6 of 34 participants (17.6%) reported occasional alcohol intake (<1 drink/week), and 28 participants (82.4%) maintained complete abstinence. Seven of 10 participants (70.0%) in the intervention group who were current smokers at baseline attained complete smoking cessation at the intervention endpoint, and 3 of 10 participants (30.0%) reduced their tobacco consumption by 45% to 75%. At 6 months after intervention, 9 of 10 participants (90.0%) achieved and maintained complete smoking cessation.

Participants in the intervention group also had significant improvements in physical activity and dietary behaviors at both the intervention endpoint (change in physical activity, 8.8 km/d [95% CI, 7.3-10.4 km/d]; change in Food Behavior Checklist score, 12.0 points [95% CI, 9.5-14.5 points]) and 6 months after intervention (eg, physical component summary score: change at 8 weeks, 6.0 points [95% CI, 2.4-9.7 points] vs 2.5 points [95% CI, -1.3 to 6.2 points]; change at 6 months, 6.5 points [95% CI, 2.6-10.3 points] vs -0.02 points [95% CI, -4.2 to 4.1 points]) (eTable 7 in Supplement 2). No significant changes in these health-related quality of life end points from the intervention endpoint to 6 months after intervention were found (eTable 8 in Supplement 2).

### Table 3. Secondary Body Composition and Cardiometabolic Risk End Points (continued)

| End point            | Control group (n = 49) | Intervention group (n = 40) | Mean difference between groups* |
|----------------------|------------------------|----------------------------|---------------------------------|
| γ-GT, IU/L (95% CI)  |                        |                            |                                 |
| Baseline             | 44.1 (34.6 to 53.6)    | 38.2 (27.9 to 48.5)        | NA                              |
| Change at 8 wk       | 3.7 (-4.7 to 12.0)     | -11.2 (-18.9 to -3.5)      | -14.9 (-24.2 to -5.6)*          |
| Change at 6 mo       | 0.5 (-8.4 to 9.5)      | -14.0 (-22.2 to -5.9)      | -14.6 (-24.5 to -4.6)*          |
| Fatty liver index, score (95% CI) |          |                            |                                 |
| Baseline             | 85.7 (80.5 to 90.8)    | 86.2 (80.6 to 91.7)        | NA                              |
| Change at 8 wk       | -1.5 (-6.3 to 3.3)     | -13.7 (-18.0 to -9.4)      | -12.2 (-17.5 to -6.9)*          |
| Change at 6 mo       | -0.1 (-5.1 to 5.0)     | -17.5 (-22.1 to -12.9)     | -17.4 (-23.0 to -11.8)*         |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, Homeostasis Model Assessment for Insulin Resistance; LDL-C, low-density lipoprotein cholesterol; γ-GT, γ-glutamyltransferase; NA, not applicable.

SI conversion factors: To convert ALT to μkat/L, multiply by 0.017; to convert apolipoprotein A1 to g/L, multiply by 0.01; to convert apolipoprotein B to g/L, multiply by 0.01; to convert AST to μkat/L, multiply by 0.017; to convert γ-GT to μkat/L, multiply by 0.017; to convert glucose to mmol/L, multiply by 0.05551; to convert HDL-C to mmol/L, multiply by 0.02586; to convert insulin to pmol/L, multiply by 6.945; to convert LDL-C to mmol/L, multiply by 0.02586; to convert total cholesterol to mmol/L, multiply by 0.02586; to convert triglycerides to mmol/L, multiply by 0.01129.

* Derived using the group × visit interaction term from a linear mixed-effects model that included study group, time (baseline, 8 weeks, and 6 months), and study group × time interaction term as fixed effects and participant as random effect.

** P < .001 for time × study group interactions.

* P = .006 for time × study group interactions.

* P = .03 for time × study group interactions.

* P = .002 for time × study group interactions.

* P = .02 for time × study group interactions.

* P = .001 for time × study group interactions.

* The HOMA-IR range in the study sample was 0.09 to 11.7. Values higher than 1.85 were considered to be indicators of insulin resistance in this sample of Spanish men.

* P = .005 for time × study group interactions.

* P = .01 for time × study group interactions.

* P = .003 for time × study group interactions.
months after intervention (change in physical activity, 6.0 km/d [95% CI, 4.3-7.6 km/d]; change in Food Behavior Checklist score, 9.2 points [95% CI, 6.5-11.9 points]) (eTable 9 in Supplement 2), although slight reductions from the intervention end point to 6 months after intervention were found in both end points (change in physical activity, −2.8 km/d [95% CI, −4.5 to −1.2 km/d]; change in Food Behavior Checklist score, −2.8 points [95% CI, −5.5 to −0.1 points]) (eTable 10 in Supplement 2). No discernible differences in lifestyle habits were found among participants in the control group from baseline to the intervention end point or from baseline to 6 months after intervention.

Adverse Events
No serious adverse events that led to death, life-threatening illness, permanent impairment, or hospitalization with serious health conditions, related or unrelated to the study intervention or participation, occurred from baseline to the intervention end point or from baseline to 6 months after intervention.

Discussion
This randomized clinical trial showed that a novel 8-week interdisciplinary weight loss and lifestyle intervention that was carefully designed to conform to existing evidenced-based clinical practice guidelines22,23,47,48 led to improvement or even remission of OSA and coexisting conditions among adults with moderate to severe OSA who had overweight or obesity and were receiving CPAP therapy. Although recommended, weight loss and lifestyle interventions for OSA treatment are rarely implemented for the care of patients with this condition because of the modest quality of evidence and the methodological weaknesses present in this field of research.22,23

The weight loss and lifestyle intervention group had a clinically meaningful reduction in AHI of 51% at the intervention end point; 15.0% of participants attained complete remission of OSA, and 45.0% no longer required CPAP therapy. After 6 months, the reduction in AHI was 57%; complete remission of OSA was attained by 29.4% of participants, and 61.8% no longer required CPAP therapy. The intervention group notably exhibited similar reductions of 7% in body weight, 19% in fat mass, and 26% in visceral adipose tissue at 6 months after intervention. Furthermore, these results were strengthened by the evidence of significant improvement in important cardiometabolic end points involved in the pathogenesis of cardiovascular diseases. Based on reductions in systolic and diastolic blood pressure observed at the intervention end point, which were not only sustained but significantly increased at 6 months after intervention, the intervention group may have lowered their risk of stroke death by 40% and lowered their risk of death from ischemic heart disease or other vascular causes by 30%.54

To our knowledge, these results are representative of the best achieved using current behavioral approaches.24 The mechanisms by which weight loss and lifestyle changes substantially ameliorate OSA and coexisting conditions are probably multifactorial. Gathered evidence suggests that almost 60% of moderate to severe OSA is associated with obesity,55 which contributes to alterations of the airway anatomy and collapsibility as well as respiratory modulation.21 We found that reductions in BMI were significantly associated with changes in AHI over time. Adverse lifestyle behaviors, such as poor diet, low physical activity levels, smoking, and alcohol intake, have also been reported to be associated with OSA independent of body habitus.31-33,56 Thus, a combination of both weight loss and lifestyle changes may even resolve OSA in individuals with overweight or obesity.5,23

In addition, there is a well-recognized dose-dependent relationship between weight loss and improvement in cardiometabolic end points, with weight loss of even 5% resulting in enhanced metabolic function.57 Given that OSA and obesity act synergistically and have independent associations with cardiovascular risk,21 the beneficial effects of weight loss on cardiometabolic risk factor profiles are likely to be heightened in patients with both obesity and OSA.
Strengths and Limitations

This study has several strengths. A major strength is the balance in the efficacy-effectiveness continuum achieved by our clinical trial, with a satisfactory internal validity accompanied by a high degree of generalizability due to our inclusion and exclusion criteria. The eligibility criteria were based on a thorough consideration of the potential generalizability of results; thus, no criteria regarding potential responsiveness, comorbidities, adherence rates, or use of nonhypnotic medications were established. Our sample therefore reflected the heterogeneity of the population with OSA. Given the study design and significant results obtained, this clinical trial may provide a clear and compelling rationale for the use of an alternative approach that is readily adaptable to real-world practice settings. Another strength is the study's inclusion of smoking and alcohol avoidance, factors that have not been previously considered despite their recognized association with the occurrence and worsening of OSA.

The study also has limitations. A main limitation is the sole inclusion of men in the study sample; the generalization of our findings is therefore limited to this population. The sample also included only Spanish participants; thus, our results are restricted to this ethnic population. Although this study included a 6-month follow-up assessment, the study's duration may not have been sufficient to determine long-term intervention effects and maintenance of benefits. Due to ethical considerations, we did not include any group for whom no therapy was provided; CPAP therapy is the standard of care for moderate to severe OSA, and the inclusion of a group not receiving CPAP therapy may not be feasible.

Conclusions

In this randomized clinical trial involving Spanish men with moderate to severe OSA receiving CPAP therapy, an 8-week interdisciplinary weight loss and lifestyle intervention resulted in clinically meaningful and sustainable improvements in specific OSA-related outcomes and cardiometabolic comorbidities as well as increased health-related quality of life. Given the high prevalence of OSA, its complex and reciprocal interaction with obesity, and the fact that both conditions are readily treatable through an integrated behavioral intervention, health care professionals and policy makers might consider this approach as a central strategy to address the substantial impact of OSA on the health and welfare of populations.
**Author Contributions:** Dr Carneiro-Barrera had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Carneiro-Barrera, Amaro-Gahete, Guillén-Riquelme, Jurado-Fasoli, Sáez-Roca, Buela-Casal, Ruiz.

**Acquisition, analysis, or interpretation of data:** Carneiro-Barrera, Amaro-Gahete, Guillén-Riquelme, Martín-Carrasco, Buela-Casal, Ruiz.

**Drafting of the manuscript:** Carneiro-Barrera, Amaro-Gahete, Ruiz.

**Critical revision of the manuscript for important intellectual content:** All authors.

**Statistical analysis:** Carneiro-Barrera, Amaro-Gahete, Guillén-Riquelme.

**Obtained funding:** Carneiro-Barrera, Amaro-Gahete, Buela-Casal.

**Administrative, technical, or material support:** Carneiro-Barrera, Amaro-Gahete, Guillén-Riquelme, Jurado-Fasoli, Martín-Carrasco, Buela-Casal, Ruiz.

**Supervision:** Carneiro-Barrera, Amaro-Gahete, Martín-Carrasco, Buela-Casal, Ruiz.

**Conflict of Interest Disclosures:** None reported.

**Funding/Support:** This study was supported by grants FPU16/01093 (Dr Carneiro-Barrera), FPU14/04172 (Dr Amaro-Gahete), and FPU19/01609 (Mr. Jurado-Fasoli) from the Spanish Ministry of Education and Vocational Training; grant SDM/M16107/UGR (via European Regional Development Funds) from the Junta de Andalucía, Consejería de Conocimiento, Investigación y Universidades (Dr Ruiz); and funding from the University of Granada-LoMonaco S.L. Sleep Research Cathedra and the University of Granada Plan Propio de Investigación 2016-Excellence Actions: Unit of Excellence on Exercise and Health.

**Role of the Funder/Sponsor:** The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Data Sharing Statement:** See Supplement 3.

**Additional Contributions:** We express our deepest gratitude to the participants for their involvement in the study, Lo Monaco S.L. and TEA Ediciones S.A. provided valuable equipment and technical support for research. Imran Khan, MSc, of the University of Greenwich, London, United Kingdom, provided diligent writing assistance and language editing. He was not compensated outside his usual salary.

**REFERENCES**

1. Benjafeld AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. *Lancet Respir Med*. 2019;7(8):687-698. doi:10.1016/S2213-2600(19)30198-5

2. Senaratna CV, Perret JL, Lodge CJ, et al. Prevalence of obstructive sleep apnea in the general population: a systematic review. *Sleep Med Rev*. 2017;34:70-81. doi:10.1016/j.smrv.2016.07.002

3. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1923-1994. doi:10.1016/S0140-6736(18)32225-6

4. Gottlieb DJ, Punjabi NM. Diagnosis and management of obstructive sleep apnea: a review. *JAMA*. 2020;323(14):1389-1400. doi:10.1001/jama.2020.3514

5. Veasey SC, Rosen IM. Obstructive sleep apnea in adults. *N Engl J Med*. 2019;380(15):1442-1449. doi:10.1056/NEJMcp1816152

6. Morsy NE, Farrag NS, Zaki NFW, et al. Obstructive sleep apnea: personal, societal, public health, and legal implications. *Rev Environ Health*. 2019;34(2):153-169. doi:10.1515/reveh-2018-0068

7. Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia—revisited—the bad ugly and good: implications to the heart and brain. *Sleep Med Rev*. 2015;20:27-45. doi:10.1016/j.smrv.2014.07.003

8. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med*. 2000;342(19):1378-1384. doi:10.1056/NEJM200005133421901

9. Nadeem R, Singh M, Nida M, et al. Effect of obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis. *J Clin Sleep Med*. 2014;10(5):475-489. doi:10.5664/jcsm.3690

10. Aurora RN, Punjabi NM. Obstructive sleep apnoea and type 2 diabetes mellitus: a bidirectional association. *Lancet Respir Med*. 2013;1(4):329-338. doi:10.1016/S2213-2600(13)70039-0
11. Marin JM, Carrizo SJ, Vicente E, Agustí AGN. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet*. 2005;365(9464):1046-1053. doi:10.1016/S0140-6736(05)71141-7

12. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. *Sleep*. 2008;31(8):1071-1078.

13. Basner RC. Continuous positive airway pressure for obstructive sleep apnea. *N Engl J Med*. 2007;356(17):1751-1758. doi:10.1056/NEJMct066953

14. Sawyer AM, Gooneratne NS, Marcus CL, Ofer D, Richards KC, Weaver TE. A systematic review of CPAP adherence across age groups: clinical and empiric insights for developing CPAP adherence interventions. *Sleep Med Rev*. 2011;15(6):343-356. doi: 10.1016/j.smrv.2011.01.003

15. Yu J, Zhou Z, McEvoy RD, et al. Association of positive airway pressure with cardiovascular events and death in adults with sleep apnea: a systematic review and meta-analysis. *JAMA*. 2017;318(2):156-166. doi:10.1001/jama.2017.7967

16. Ifitikhar IH, Valentine CW, Bittencourt LRA, et al. Effects of continuous positive airway pressure on blood pressure in patients with resistant hypertension and obstructive sleep apnea: a meta-analysis. *J Hypertens*. 2014;32(12):2341-2350. doi:10.1097/JHJ.0000000000000372

17. Ifitikhar IH, Hoyos CM, Phillips CL, Magalan UJ. Meta-analyses of the association of sleep apnea with insulin resistance, and the effects of CPAP on HOMA-IR, adiponectin, and visceral adipose fat. *J Clin Sleep Med*. 2015;11(4):475-485. doi:10.5664/jcsm.4610

18. Barbe F, Durán-Cantolla J, Sánchez-de-la-Torre M, et al; Spanish Sleep And Breathing Network. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. *JAMA*. 2012;307(20):2161-2168. doi:10.1001/jama.2012.4366

19. McEvoy RD, Antic NA, Heelley E, et al; SAVE Investigators and Coordinators. CPAP for prevention of cardiovascular events in obstructive sleep apnea. *N Engl J Med*. 2016;375(10):919-931. doi:10.1056/NEJMoal606599

20. Craig SE, Kohler M, Nicoll D, et al. Continuous positive airway pressure improves sleepiness but not calculated vascular risk in patients with minimally symptomatic obstructive sleep apnoea: the MOSAIC randomised controlled trial. *Thorax*. 2012;67(12):1090-1096. doi:10.1136/thoraxjnl-2012-202178

21. Ong CW, O'Driscoll DM, Truby H, Naughton MT, Hamilton GS. The reciprocal interaction between obesity and obstructive sleep apnoea. *Sleep Med Rev*. 2013;17(2):123-131. doi:10.1016/j.smrv.2012.05.002

22. Epstein LJ, Kristo D, Strollo PJJr, et al; Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med*. 2009;5(3):263-276. doi:10.5664/jcsm.27497

23. Hudgel DW, Patel SR, Ahasic AM, et al; American Thoracic Society Assembly on Sleep and Respiratory Neurobiology. The role of weight management in the treatment of adult obstructive sleep apnea: an official American Thoracic Society clinical practice guideline. *Am J Respir Crit Care Med*. 2018;198(6):e70-e87. doi:10.1164/rccm.201807-1326ST

24. Carneiro-Barrera A, Díaz-Román A, Guillén-Riquelme A, Buela-Casal G. Weight loss and lifestyle interventions for obstructive sleep apnoea in adults: systematic review and meta-analysis. *Obes Rev*. 2019;20(5):750-762. doi:10.1111/obr.12824

25. Foster GD, Borradaile KE, Sanders MH, et al; Sleep AHEAD Research Group of Look AHEAD Research Group. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. *Arch Intern Med*. 2009;169(17):1619-1626. doi:10.1001/archinternmed.2009.266

26. Johansson K, Neovius M, Lagerros YT, et al. Effect of a very low energy diet on moderate and severe obstructive sleep apnoea in obese men: a randomised controlled trial. *BMJ*. 2009;339:b4609. doi:10.1136/bmj.b4609

27. Tuomilehto H, Seppä J, Uusituupa M, Tuomilehto J, Gylling H; Kuopio Sleep Apnea Group FT. Weight reduction and increased physical activity to prevent the progression of obstructive sleep apnea: a 4-year observational postintervention follow-up of a randomized clinical trial. [corrected]. *JAMA Intern Med*. 2013;173(10):929-930. doi:10.1001/jamainternmed.2013.389
28. Sampson M, Clark A, Bachmann M, et al; Norfolk Diabetes Prevention Study (NDPS) Group. Lifestyle intervention with or without lay volunteers to prevent type 2 diabetes in people with impaired fasting glucose and/or nondiabetic hyperglycemia: a randomized clinical trial. *JAMA Intern Med.* 2021;181(2):168-178. doi:10.1001/jamainternmed.2020.5938

29. O'Connor EA, Evans CV, Rushkin MC, Redmond N, Lin JS. Behavioral counseling to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA.* 2020;324(20):2076-2094. doi:10.1001/jama.2020.7108

30. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. *J Clin Epidemiol.* 2009;62(5):464-475. doi:10.1016/j.jclinepi.2008.12.011

31. Kolla BP, Foroughi M, Saeidifard F, Chakravorty S, Wang Z, Mansukhani MP. The impact of alcohol on breathing parameters during sleep: a systematic review and meta-analysis. *Sleep Med Rev.* 2018;42:59-67. doi:10.1016/j.smrv.2018.05.007

32. Krishnan V, Dixon-Williams S, Thornton JD. Where there is smoke...there is sleep apnea: exploring the relationship between smoking and sleep apnea. *Chest.* 2014;146(6):1673-1680. doi:10.1378/chest.14-0772

33. Carneiro-Barrera A, Amaro-Gahete FJ, Díaz-Román A, et al. Interdisciplinary weight loss and lifestyle intervention for obstructive sleep apnoea in adults: rationale, design and methodology of the INTERAPNEA study. *Nutrients.* 2019;11(9):2227. doi:10.3390/nu11092227

34. Basoglu OK, Tasbakan MS. Gender differences in clinical and polysomnographic features of obstructive sleep apnea: a clinical study of 2827 patients. *Sleep Breath.* 2018;22(1):241-249. doi:10.1007/s11325-017-1482-9

35. Robertson C, Avenell A, Boachie C, et al. Should weight loss and maintenance programmes be designed differently for men? a systematic review of long-term randomised controlled trials presenting data for men and women: the ROMEO project. *Obes Res Clin Pract.* 2016;10(1):70-84. doi:10.1016/j.orcp.2015.04.005

36. Williams RL, Wood LG, Collins CE, Callister R. Effectiveness of weight loss interventions--is there a difference between men and women: a systematic review. *Obes Rev.* 2015;16(2):171-186. doi:10.1111/obr.12241

37. Harreiter J, Kautzky-Willer A. Sex and gender differences in prevention of type 2 diabetes. *Front Endocrinol (Lausanne).* 2018;9:220. doi:10.3389/fendo.2018.00220

38. Schulz K, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. *Lancet.* 2002;359(9305):515-519. doi:10.1016/S0140-6736(02)07683-3

39. Friedberg JP, Lipsitz SR, Natarajan S. Challenges and recommendations for blinding in behavioral interventions illustrated using a case study of a behavioral intervention to lower blood pressure. *Patient Educ Couns.* 2010;78(1):5-11. doi:10.1016/j.pec.2009.04.009

40. Buysee DJ, Reynolds CF III, Monk TH, Berman SR, Kuper DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res.* 1989;28(2):193-213. doi:10.1016/0165-1781(89)90047-4

41. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. *Sleep.* 1991;14(6):540-545. doi:10.1093/sleep/14.6.540

42. Flemons WW, Reimer MA. Development of a disease-specific health-related quality of life questionnaire for sleep apnea. *Am J Respir Crit Care Med.* 1998;158(2):494-503. doi:10.1164/ajrccm.158.2.9712036

43. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). I. conceptual framework and item selection. *Med Care.* 1992;30(6):473-483.

44. Ware JE Jr. SF-36 Health Survey: Manual and Interpretation Guide. Nimrod Press; 1993.

45. Banna JC, Townsend MS. Assessing factorial and convergent validity and reliability of a food behaviour checklist for Spanish-speaking participants in US Department of Agriculture nutrition education programmes. *Public Health Nutr.* 2011;14(7):1165-1176. doi:10.1017/S1368980010003058

46. Therapeutic Goods Administration, Commonwealth Department of Health and Aged Care. Note for guidance on clinical safety data management: definitions and standards for expedited reporting (CPMP/ICH/377/95). July 2000. Accessed February 6, 2019. https://www.tga.gov.au/sites/default/files/ich37795.pdf

47. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. *N Engl J Med.* 2017;376(3):254-266. doi:10.1056/NEJMra1514009

48. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Expert panel report: guidelines (2013) for the management of overweight and obesity in adults. *Obesity (Silver Spring).* 2014;22(suppl 2):S41-S410. doi:10.1002/oby.20660
49. Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *J Stat Softw.* 2015;67(1):1-48. doi:10.18637/jss.v067.i01

50. Cro S, Morris TP, Kahan BC, Cornelius VR, Carpenter JR. A four-step strategy for handling missing outcome data in randomised trials affected by a pandemic. *BMC Med Res Methodol.* 2020;20(1):208. doi:10.1186/s12874-020-01089-6

51. Bakdash JZ, Marusich LR. Repeated measures correlation. *Front Psychol.* 2017;8:456. doi:10.3389/fpsyg.2017.00456

52. Wasserstein RL, Schirm AL, Lazar NA. Moving to a world beyond “p < 0.05”. *Am Stat.* 2019;73(suppl 1):1-19. doi:10.1080/00031305.2019.1583913

53. Pogrow S. How effect size (practical significance) misleads clinical practice: the case for switching to practical benefit to assess applied research findings. *Am Stat.* 2019;73(suppl 1):223-234. doi:10.1080/00031305.2018.1549101

54. Lewington S, Clarke R, Qizilbash N, Petro R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet.* 2002;360(9349):1903-1913. doi:10.1016/S0140-6736(02)11911-8

55. Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. *J Appl Physiol (1985).* 2005;99(4):1592-1599. doi:10.1152/japplphysiol.00587.2005

56. Peppard PE, Young T. Exercise and sleep-disordered breathing: an association independent of body habitus. *Sleep.* 2004;27(3):480-484. doi:10.1093/sleep/27.3.480

57. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. *Cell Metab.* 2016;23(4):591-601. doi:10.1016/j.cmet.2016.02.005

**SUPPLEMENT 1.**
Trial Protocol

**SUPPLEMENT 2.**
eMethods 1. Study Organization and Eligibility Criteria
eMethods 2. Study Assessments and End Points
eMethods 3. Weight Loss and Lifestyle Intervention
eMethods 4. Assessment of Adherence and Integrity of Intervention and Intervention Adherence
eTable 1. Missing Values in Secondary Cardiometabolic Risk End Points
eTable 2. Baseline Characteristics of Study Participants (Per-Protocol Approach)
eTable 3. Primary and Secondary Sleep-Related End Points (Per-Protocol Approach)
eTable 4. Primary and Secondary Sleep-Related End Points (Change From 8 Weeks to 6 Months)
eTable 5. Secondary Body Composition and Cardiometabolic Risk End Points (Per-Protocol Approach)
eTable 6. Secondary Body Composition and Cardiometabolic Risk End Points (Change From 8 Weeks to 6 Months)
eTable 7. Health-Related Quality of Life End Points
eTable 8. Health-Related Quality of Life End Points (Change From 8 Weeks to 6 Months)
eTable 9. Physical Activity and Dietary Behavior End Points
eTable 10. Physical Activity and Dietary Behavior End Points (Change From 8 Weeks to 6 Months)
eFigure 1. Obstructive Sleep Apnea Severity at Baseline and 8 Weeks After Intervention in the Intervention Group
eFigure 2. Apnea-Hypopnea Index End Point (Change From 8 Weeks to 6 Months)
eFigure 3. Association Between Changes in Apnea-Hypopnea Index Over Time and Changes in Body Mass Index
eReferences

**SUPPLEMENT 3.**
Data Sharing Statement